CTI-1601 is similar to frataxin, except it has a Cell Penetrating Peptide (CPP) attached on the end to allow it to move into the cell and mitochondria.
A process diagram for Larimar’s program for Friedreich’s ataxia, CTI-1601.
Larimar therapeutics
The Larimar Therapeutics site has several infographics to illustrate their proprietary protein replacement therapy platform and its potential to deliver missing proteins inside the machinery of cells.
Designed while employed at Fassino/Design.